US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at -0.05 against a street estimate of -0.17 — a beat of 70.6%.
Analysts rate Biofrontera Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $6.00.
| Fund | Stake |
|---|---|
| Rosalind Advisors, Inc. | 8.59% |
| AIGH Capital Management, LLC | 4.98% |
| Renaissance Technologies Corp | 1.06% |
| Citadel Advisors Llc | 0.71% |
| Jane Street Group LLC | 0.63% |
| Geode Capital Management, LLC | 0.52% |
| Vanguard Capital Management, LLC | 0.48% |
| Vanguard Fiduciary Trust Co | 0.42% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Biofrontera Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.